Pfizer

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Pfizer 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About PFE

Pfizer Inc. is a research-based global biopharmaceutical company, which engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm works across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases. 

CEO
Albert Bourla
CEOAlbert Bourla
Employees
81,000
Employees81,000
Headquarters
New York, New York
HeadquartersNew York, New York
Founded
1849
Founded1849
Employees
81,000
Employees81,000

PFE Key Statistics

Market cap
145.81B
Market cap145.81B
Price-Earnings ratio
14.95
Price-Earnings ratio14.95
Dividend yield
6.71%
Dividend yield6.71%
Average volume
49.86M
Average volume49.86M
High today
$25.79
High today$25.79
Low today
$25.51
Low today$25.51
Open price
$25.59
Open price$25.59
Volume
45.40M
Volume45.40M
52 Week high
$27.69
52 Week high$27.69
52 Week low
$20.92
52 Week low$20.92

Stock Snapshot

With a market cap of 145.81B, Pfizer(PFE) trades at $25.61. The stock has a price-to-earnings ratio of 14.95 and currently yields dividends of 6.7%.

On 2026-01-24, Pfizer(PFE) stock moved within a range of $25.51 to $25.79. With shares now at $25.61, the stock is trading +0.4% above its intraday low and -0.7% below the session's peak.

Trading volume for Pfizer(PFE) stock has reached 45.4M, versus its average volume of 49.86M.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

Over the past 52 weeks, Pfizer(PFE) stock has traded between a high of $27.69 and a low of $20.92.

PFE News

Nasdaq 2h
The Best Stocks to Invest $40 in to Start the New Year Off Right

Key Points Pfizer's deep pipeline could prove its greatest asset, helping it bounce back. Viking Therapeutics is developing a highly promising weight loss med...

The Best Stocks to Invest $40 in to Start the New Year Off Right
Simply Wall St 12h
Pfizer Refocuses Portfolio With Matrix M Deal And ViiV Exit

Pfizer (NYSE:PFE) has entered a non exclusive licensing agreement to use Novavax’s Matrix M adjuvant technology in up to two infectious disease vaccine programs...

Pfizer Refocuses Portfolio With Matrix M Deal And ViiV Exit
Benzinga 1d
Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research

Pfizer Inc. (NYSE:PFE) CEO Albert Bourla sharply criticized Robert F. Kennedy's views on vaccines, calling them "anti-science." He suggested that meaningful pr...

Pfizer CEO Calls RFK's Vaccine Views Anti-Science, Warns US Falling Behind China In Health Research

Analyst ratings

57%

of 28 ratings
Buy
39.3%
Hold
57.1%
Sell
3.6%

More PFE News

TipRanks 1d
Mixed options sentiment in Pfizer with shareslittle changed

Mixed options sentiment in Pfizer (PFE), with shares down 2c near $25.64. Options volume roughly in line with average with 61k contracts traded and calls leadin...

TipRanks 1d
Pfizer’s New Autoimmune Candidate PF-08065010 Enters Phase 1: What Investors Should Watch

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview: Pfizer is launching a new early-stage tri...

TipRanks 1d
Pfizer Takes Aim at Keytruda in New Phase 3 Lung Cancer Study: What Investors Should Know

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

TipRanks 1d
Pfizer Advances New COPD Candidate Into Phase 2/3, Adding Depth to Its Post-COVID Pipeline

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Study Overview Pfizer has launched a phase 2/3 trial (NC...

CNBC 1d
What obesity drugmakers see next in the market: More pills, easier access and drug combinations

Key Points Top executives from drugmakers big and small told CNBC that the next phase of the obesity drug market will be defined by a broader range of treatment...

What obesity drugmakers see next in the market: More pills, easier access and drug combinations
Simply Wall St 2d
Pfizer Valuation Check As Shares Recover Modestly From Longer Term Weakness

Advertisement Recent performance snapshot for Pfizer (PFE) Pfizer (PFE) has moved quietly higher in recent months, with a 1-month return of 4.9% and a past 3-...

Pfizer Valuation Check As Shares Recover Modestly From Longer Term Weakness
TipRanks 2d
Pfizer Advances PF-07248144 With New Drug–Interaction Study, Signaling Quiet Pipeline Progress

Pfizer Inc (PFE) announced an update on their ongoing clinical study. Claim 50% Off TipRanks Premium Unlock hedge fund-level data and powerful investing tools f...

People also own

Based on the portfolios of people who own PFE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.